The Latest Breaking News from Novo Nordisk

The drugs, although not officially approved for use in weight loss, have been touted as a “miracle” treatments for obesity.

Barclays strategists expect "disruption into a number of industries," thanks to drugs like Novo Nordisk's Ozempic and Wegovy.

Hailed as potential ‘game changer’ in tackling obesity, Semaglutide can also help those with type 2 diabetes

The study represents the first long-term, large-scale, real-world trial of the blockbuster drug, researchers said.

Researchers said semaglutide’s effectiveness in treating type 2 diabetes has been shown in some trials, but long-term data is ‘lacking’.

Danish pharmaceutical company Novo Nordisk has signed a deal with South Africa’s Aspen Pharmacare to produce human insulin specifically for diabetes patients in Africa where there is a dire need for the life-saving treatment

These three biotech stocks have massive growth opportunities on the horizon, and could add a huge boost to any portfolio. They play in some of the most in demand markets on the planet, and have track records of finding ways to introduce products into those markets to capture big profits.…

Novo Nordisk, the maker of the blockbuster obesity injection, has singlehandedly saved the country from recession

Ozempic has not shown increased risk of suicidal ideation in trials, but some users say it harmed their mental health.

In February 2021, The Conversation reported on a trial for a new weight-loss drug, called semaglutide, that was being hailed in the media as a “gamechanger”. Gamechanger is a word used far too often by journalists to describe things that are, frankly, mundane. This time, though, the word seems apt.

The Danish pharma giant overtook French luxury conglomerate LVMH as the most valuable European company, which held the title since 2021.